Loading patent…
AssigneesBiodesix, Inc., GlobeImmune, Inc.
InventorsJoanna Röder, Heinrich Röder
Estimating the term…
A method and system for predicting in advance of treatment whether a cancer patient is likely, or not likely, to obtain benefit from administration of a yeast-based immune response generating therapy, which may be yeast-based immunotherapy for mutated Ras-based cancer, alone or in combination with another anti-cancer therapy. The method uses mass spectrometry of a blood-derived patient sample and a computer configured as a classifier using a training set of class-labeled spectra from other cancer patients that either benefited or did not benefit from an immune response generating therapy alone or in combination with another anti-cancer therapy. Also disclosed are methods of treatment of a cancer patient, comprising administering a yeast-based immune response generating therapy, which may be yeast-based immunotherapy for mutated Ras-based cancer, to a patient selected by a test in accordance with predictive mass spectral methods disclosed herein, in which the class label for the spectra indicates the patient is likely to benefit from the yeast-based immunotherapy.
A method for treating a cancer, comprising administering yeast-based immunotherapy for cancer to a cancer patient, wherein the patient has been selected by a mass spectrometry and classification test, the test comprising the steps of:
A method for treating a cancer, comprising administering yeast-based immunotherapy for cancer to a cancer patient, wherein the patient has been selected by a mass spectrometry and classification test, the test comprising the steps of:
A method of predicting whether a cancer patient is likely to benefit from administration of a yeast-based immunotherapy for cancer, either alone or in addition to another anti-cancer therapy, comprising the steps of:
Dependencies are inferred from the claim text.